• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OS Therapies Incorporated

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SC 13G 1 tm2422947d1_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    OS THERAPIES INCORPORATED

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    68764Y207

     

    (CUSIP Number)

     

    August 2, 2024

     

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     

    *               The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     

    Page 1 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    1.NAMES OF REPORTING PERSONS

     

    Thomas A. Satterfield, Jr.

     

    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)¨
    (b)¨

     

    3.SEC USE ONLY

     

    4.CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.SOLE VOTING POWER

     

    50,000

     

    6.SHARED VOTING POWER

     

    1,244,989

     

    7.SOLE DISPOSITIVE POWER

     

    50,000

     

    8.SHARED DISPOSITIVE POWER

     

    1,244,989

     

    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,294,989

     

    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

     

    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.20%*

     

    12.TYPE OF REPORTING PERSON

     

    IN

      

    * Based on 20,884,575 shares of common stock of the issuer outstanding as of August 14, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024.

     

    Page 2 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    SCHEDULE 13G

     

    Item 1.

     

    (a)Name of Issuer:

     

    OS Therapies Incorporated

     

    (b)Address of Issuer's Principal Executive Offices:

     

    115 Pullman Crossing Road, Suite 103

    Grasonville, Maryland 21638

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Thomas A. Satterfield, Jr.

     

    (b)Address of Principal Business Office or, if none, Residence:

     

    Thomas A. Satterfield, Jr.

    15 Colley Cove Drive

    Gulf Breeze, Florida 32561

     

    (c)Citizenship:

     

    Incorporated by reference from Item 4 of the Cover Page.

     

    (d)Title of Class of Securities:

     

    Incorporated by reference from the Cover Page.

     

    (e)CUSIP Number:

     

    Incorporated by reference from the Cover Page.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Incorporated by reference from Item 9 of the Cover Page.

     

    (b)Percent of class:

     

    Incorporated by reference from Item 11 of the Cover Page.

     

    Page 3 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    Incorporated by reference from Item 5 of the Cover Pages.

     

    (ii)Shared power to vote or to direct the vote

     

    Incorporated by reference from Item 6 of the Cover Pages.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 7 of the Cover Pages.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 8 of the Cover Pages.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 50,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 112,500 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 1,082,489 shares are held by Satterfield Vintage Investments, L.P. Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of Satterfield Vintage Investments, L.P.’s equity, and Tomsat Investment & Trading Co., Inc. is the general partner of Satterfield Vintage Investments, L.P.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Page 4 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 28, 2024
      Date
       
      /s/ Thomas A. Satterfield, Jr.
      Thomas A. Satterfield, Jr.

     

     

    Get the next $OSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Former 10% Owner Auerbach Shalom

      4 - OS Therapies Inc (0001795091) (Issuer)

      5/9/25 9:45:04 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom sold $163,918 worth of shares (82,000 units at $2.00) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      5/9/25 9:30:13 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom sold $81,566 worth of shares (60,012 units at $1.36) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      4/11/25 9:45:07 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OS Therapies with a new price target

      Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

      4/2/25 8:01:55 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

      NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma. OST-HER2, a Listeria monocytogenes-based immunotherapy, is the first potential new treatment in over 40 years for pediatric os

      6/10/25 7:40:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

      If awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation RMAT designation reduces BLA application review time and permits augmented interactions with FDA to inform market access OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative

      6/6/25 7:30:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

      Feedback from Type D FDA Meeting expected by mid-June 2025 to confirm statistical analysis methods to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation requests Completed Phase 2b trial data analysis using methods agreed to by FDA to be presented at MIB Factor on June 28, 2025 Company remains on track for Q3 2025 BLA filing for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial res

      5/16/25 6:00:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by OS Therapies Incorporated

      EFFECT - OS Therapies Inc (0001795091) (Filer)

      6/9/25 12:15:23 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by OS Therapies Incorporated

      S-1 - OS Therapies Inc (0001795091) (Filer)

      5/23/25 4:51:41 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OS Therapies Inc (0001795091) (Filer)

      5/16/25 4:05:12 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care